Status:
UNKNOWN
Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients
Lead Sponsor:
Taipei Medical University WanFang Hospital
Conditions:
Lung Cancer Patients
Eligibility:
All Genders
20+ years
Brief Summary
We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.
Eligibility Criteria
Inclusion
- 20 or more than 20 years of age
- The pathological diagnosis confirmed lung cancer
- Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens
- The patient had signed inform consent
Exclusion
- pleural effusion or tumor tissue can not be obtained
- the patient is not suitable to join the research according to the judgement by the investigator
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01257308
Start Date
August 1 2010
End Date
August 1 2013
Last Update
December 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Medical University - WanFang Hospital
Taipei, Taiwan